SEC Form 4 · accession 0001171843-16-012251
IMMUNOMEDICS INC · IMMU
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
David M Goldenberg
Officer — See Remarks · Director
Period of report
Sep 21, 2016
Accepted (ET)
Sep 23, 2016 · 5:00 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000722830
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2,F3 | Sep 21, 2016 | A | 106,061 | $0.00 | A | 3,464,631 | I | See Footnote |
| Common Stock | holding | — | — | — | 2,510,565 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F3,F4 | $3.30 | Sep 21, 2016 | A | 199,532 | D | — | Sep 21, 2023 | Common Stock, par value $0.01 per share | 199,532 | 199,532 | I |
Explanation of responses
- F1The reporting person's spouse, Ms. Cynthia L. Goldenberg (also known as Cynthia L. Sullivan), President and Chief Executive Officer of the Company, was granted restricted stock units pursuant to the Immunomedics, Inc. 2014 Long-Term Incentive Plan, which vest as to 25% of the shares on the first anniversary of the date of grant and as to 6.25% of the shares on a quarterly basis thereafter.
- F2Includes a total of 190,000 shares held as joint tenants by the reporting person and his spouse.
- F3Such shares are held by the reporting person's spouse, by various trusts established for the benefit of the reporting person and/or family members of the reporting person, or by a majority-owned subsidiary of the Issuer, of which the reporting person is a director. The reporting person disclaims beneficial ownership of these shares except to the extent of his pecuniary interests therein.
- F4The reporting person's spouse was granted stock options pursuant to the Immunomedics, Inc. 2014 Long-Term Incentive Plan, which vest as to 25% of the shares underlying the options on the first anniversary of the date of grant and as to 6.25% of the shares underlying the options on a quarterly basis thereafter.
Remarks
Chief Scientific Officer, Chief Patent Officer, and Chairman of the BOD